Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Inhibrx Biosciences Inc ( (INBX) ) has shared an update.
On January 21, 2025, Inhibrx Biosciences announced preliminary results from a Phase 1 trial of their therapeutic candidate ozekibart (INBRX-109) in combination with FOLFIRI for treating advanced colorectal adenocarcinoma. The trial showed promising efficacy, with one complete response and three partial responses among patients, and manageable safety profiles where most adverse events were low-grade. Encouraged by these results, Inhibrx has initiated an expansion cohort to further validate the findings, with results expected in the third quarter of 2025. This development underscores ozekibart’s potential in providing clinical benefits in heavily pretreated populations, positioning Inhibrx as an emerging player in the oncology therapeutics landscape.
More about Inhibrx Biosciences Inc
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in developing novel biologic therapeutic candidates for oncology and rare diseases. Utilizing diverse protein engineering methods, the company focuses on addressing complex target and disease biology, with a current clinical pipeline that includes key candidates such as ozekibart (INBRX-109) and INBRX-106.
YTD Price Performance: -11.54%
Average Trading Volume: 73,124
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $195.3M
For an in-depth examination of INBX stock, go to TipRanks’ Stock Analysis page.
